Japanese Journal of Medical Research
Open AccessPharmacologic Modulation of Luminal Carbohydrate Digestion Improves Insulinogenic, Glycemic and Lipid Parameters in Obese, Hyperinsulinemic T2DM Rats
Authors: Orien L Tulp, Syed AA Rizvi.
Abstract
Atherogenic plasma lipid and glycemic profiles are a common observation in obesity and adult-onset diabetes (T2DM) and may become improved following therapeutic intervention. The effects of the luminal α-glucosidase inhibitor miglitol (MIG) on carbohydrate (CHO) digestion on plasma lipid profiles were determined in groups of adult male obese SHR/Ntul//-cp rats, a genetic model that develops early-onset obesity+T2DM independently of diet. Rats were fed a USDA-formulated, complete diet containing 54% sucrose as the CHO component (Control) or the same diet containing MIG at 150 mg/kg diet admixture ad libitum for < 8 weeks. MIG resulted in a ~15% decrease in energy intake (p = < 0.05), net weight gain (p = < 0.05), and 14% decrease in adiposity (p= < 0.05), in addition to significant (p = < 0.05) decreases in fasting glucose, insulin, glycated hemoglobin, a 20% reduction in glucose area under the curve (AUC; p = < 0.05) a 15% reduction in triglycerides, p = < 0.05) and a 20% reduction in total cholesterol, α- (LDL) and β-lipoprotein (HDL) fractions (p = < 0.05, all comparisons) after the MIG regimen. Liver glucokinase, malic enzyme and glucose-6-phosphate dehydrogenase were also decreased following the MIG regimen (p = < 0.05). In conclusion, these results indicate that therapeutic αglucosidase inhibition via MIG resulted in improvements in multiple insulin-linked atherogenic parameters and may be a useful adjunct in the long-term clinical management of plasma lipid and glycemic profiles in the glucose intolerant states of obesity and T2DM.
Editor-in-Chief
View full editorial board →